INNOVIVE Pharmaceuticals
Development of novel therapeutics for oncology and hematology
About INNOVIVE Pharmaceuticals
Innovive Pharmaceuticals, Inc. was a development-stage biopharmaceutical company founded in 2004 that focused on developing and commercializing novel therapeutics for oncology and hematology. The company's strategy centered on acquiring, developing, and commercializing treatments for diseases with significant unmet medical needs and clear clinical endpoints to streamline the regulatory approval process.
The company's clinical development pipeline included four main drug candidates: INNO-406 for chronic myelogenous leukemia (CML), tamibarotene for acute promyelocytic leukemia (APL), INNO-206 for solid tumors like small cell lung cancer, and INNO-305 for acute myelogenous leukemia (AML). Innovive established its pipeline by licensing compounds from other companies. For instance, INNO-406 was licensed from Nippon Shinyaku, tamibarotene from TMRC Co., Ltd., INNO-206 from KTB Tumorforschungs GmbH, and INNO-305 from Memorial Sloan Kettering Cancer Center. Several of its products received special designations from the U.S. Food and Drug Administration (FDA); INNO-406 was granted orphan drug status for CML treatment, and tamibarotene received both Fast Track and Orphan Drug Designation for APL.
Led by CEO Steven Kelly, an industry veteran with over 18 years of pharmaceutical experience, the company managed to raise capital through various financing rounds, including an IPO in October 2006. However, the company faced financial challenges that limited its ability to fund ongoing clinical development. This led to its acquisition by CytRx Corporation (later known as LadRx) in a definitive agreement announced in June 2008 and completed in September 2008 for approximately $19.8 million. The acquisition was seen as a strategic move for CytRx to enhance its oncology portfolio with late-stage clinical candidates.
Source: Dealroom company dataAt a glance
- Founded
- 2004
- Headquarters
- New York City, United States
News
Open roles
INNOVIVE Pharmaceuticals in the New York City ecosystem
The INNOVIVE Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about INNOVIVE Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See INNOVIVE Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.